Is Beckman Coulter profitable?

Beckman Coulter is a wholly owned Danaher subsidiary and does not report standalone profit. Danaher's Diagnostics segment, which includes Beckman Coulter, made up about 41% of Danaher's $24.568B FY2025 revenue reported January 28, 2026, but no separate profit figure exists.

Who owns Beckman Coulter?

Danaher Corporation (NYSE: DHR) has owned Beckman Coulter since completing its acquisition on June 30, 2011. Beckman Coulter operates as a private operating company within Danaher's Diagnostics segment and does not trade separately.

Could AI replace Beckman Coulter's diagnostic instruments?

Unlikely soon. AI is being layered onto Beckman Coulter's hematology and lab-ops workflows via Scopio and Innovaccer Gravity, selected March 9, 2026, but wet-chemistry assay hardware, FDA/CE clearances, and reagent lock-in remain outside AI's reach.

Is Beckman Coulter doing layoffs?

No major layoffs reported. Beckman Coulter Diagnostics stated a workforce of over 11,000 employees globally in a July 23, 2026 release, and Life Sciences reported about 2,800 associates in March 2025, both signaling stable headcount.

Who is Beckman Coulter's biggest competitor?

Beckman Coulter competes with Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and BD in the top-5 IVD oligopoly, per a January 6, 2026 Mordor Intelligence ranking, plus Cytek Biosciences in flow cytometry, where active patent litigation is ongoing as of 2025-2026.

What is Beckman Coulter's flagship diagnostic product?

Recent flagship launches include the DxC 500i clinical chemistry and immunoassay analyzer, FDA-cleared March 10, 2025, and the DxU 1800 fully automated urinalysis system, launched in the US on July 23, 2026 at the ADLM conference.

Biotech tools companies · subsidiary of Danaher Corporation · United States

Beckman Coulter

beckman.com ↗

Danaher-owned maker of clinical lab diagnostics instruments and reagents.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from July 2026 · Every call on the record Checkpoint: ADLM 2026 diagnostics conference where rivals unveil competing platforms

The call

Beckman Coulter sits inside a slow-moving oligopoly of diagnostics makers where reagent contracts and regulatory clearances, not AI, decide who keeps the lab business.

Beckman Coulter makes machines and chemicals that hospitals use to run blood tests and diagnose diseases. It is hard to replace because hospitals have already installed 400,000 of these machines, they are locked into buying specific chemicals from Beckman to run them, and switching to a competitor would require new training and IT work. The main risk to watch is whether new blood tests for brain diseases like Alzheimer's take off and whether artificial intelligence tools for reading test results become strong enough that Beckman needs to buy smaller AI companies to stay competitive.

Why

AI pressure: Scopio Labs and similar AI morphology/analytics tools. AI tools read blood smears and flag results, but they plug into Beckman's hardware rather than replacing the wet-chemistry testing itself. Could AI do the core job? Unlikely.

Bigger players: Roche Diagnostics, Abbott, Siemens Healthineers. All compete for the same hospital lab contracts with closed reagent systems, but none has displaced Beckman's installed base. Could a giant copy it? No, they are blocked.

What protects it. Regulatory clearances per assay plus closed-system reagent contracts locked into hospital lab workflows across 400,000+ installed systems.

What would change this call

FDA/CE clearance of Beckman's p-Tau217 or BD-Tau blood test within 12 months. Shows whether it can scale into the neurodegenerative testing market ahead of rivals.
Danaher reports Diagnostics segment YoY growth in upcoming quarterly earnings. Indicates whether Beckman Coulter's core business is holding share within Danaher.
Outcome of Cytek Biosciences patent litigation (D. Del., No. 24-945). Would show whether Beckman Coulter's flow-cytometry IP position weakens.

Key numbers

Danaher Diagnostics segment ~41% of FY2025 revenue (2025)
400,000+ Beckman Coulter systems installed globally (2025-03-18)
Danaher FY2025 revenue $24.568B, up 2.9% YoY (2026-01-28)

Named risks

Active patent litigation against Cytek Biosciences over flow cytometry IP, ongoing 2025-2026. Severity: medium
Multiple employment discrimination lawsuits including Indiana probable-cause finding, April 2026, and Danaher-wide class action, March 2026. Severity: medium
Danaher could signal a Diagnostics segment spin-off or carve-out, altering Beckman Coulter's structural moat. Severity: low
Competing IVD launches from Roche, Abbott, Siemens at industry events like ADLM 2026 could pressure product positioning. Severity: medium
AI-native lab-operations platforms could erode reagent-contract renewals if analytics value shifts away from hardware. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Roche Diagnostics	contesting	Ranked among top-5 US IVD players alongside Beckman Coulter per Mordor Intelligence, 2026-01-06
Abbott Laboratories	contesting	Symmetric oligopoly competitor in clinical chemistry and immunoassay markets, 2026 rankings
Siemens Healthineers	contesting	Named top-5 IVD peer; faces own possible diagnostics-unit separation discussion by 2030 per analyst report
Becton Dickinson (BD)	contesting	Prior BD v. Beckman patent suit over CytoFLEX cell sorter, per USPTO PTAB records
Cytek Biosciences	gaining on	Beckman Coulter is plaintiff in active flow cytometry patent suit, D. Del. C.A. No. 24-945, 2025-2026

Questions people ask

Is Beckman Coulter profitable?: Beckman Coulter is a wholly owned Danaher subsidiary and does not report standalone profit. Danaher's Diagnostics segment, which includes Beckman Coulter, made up about 41% of Danaher's $24.568B FY2025 revenue reported January 28, 2026, but no separate profit figure exists.
Who owns Beckman Coulter?: Danaher Corporation (NYSE: DHR) has owned Beckman Coulter since completing its acquisition on June 30, 2011. Beckman Coulter operates as a private operating company within Danaher's Diagnostics segment and does not trade separately.
Could AI replace Beckman Coulter's diagnostic instruments?: Unlikely soon. AI is being layered onto Beckman Coulter's hematology and lab-ops workflows via Scopio and Innovaccer Gravity, selected March 9, 2026, but wet-chemistry assay hardware, FDA/CE clearances, and reagent lock-in remain outside AI's reach.
Is Beckman Coulter doing layoffs?: No major layoffs reported. Beckman Coulter Diagnostics stated a workforce of over 11,000 employees globally in a July 23, 2026 release, and Life Sciences reported about 2,800 associates in March 2025, both signaling stable headcount.
Who is Beckman Coulter's biggest competitor?: Beckman Coulter competes with Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and BD in the top-5 IVD oligopoly, per a January 6, 2026 Mordor Intelligence ranking, plus Cytek Biosciences in flow cytometry, where active patent litigation is ongoing as of 2025-2026.
What is Beckman Coulter's flagship diagnostic product?: Recent flagship launches include the DxC 500i clinical chemistry and immunoassay analyzer, FDA-cleared March 10, 2025, and the DxU 1800 fully automated urinalysis system, launched in the US on July 23, 2026 at the ADLM conference.

Timeline

2026-07-23Launched DxU 1800 fully automated urinalysis system in the US at ADLM 2026
2026-07Received CE Mark for p-Tau217 blood test and a rapid bacterial-vs-viral infection assay
2026-04-15Indiana Civil Rights Commission issued probable cause finding on discrimination complaint
2026-03-09Selected Innovaccer Gravity as AI and data platform for lab operations modernization
2026-01-28Danaher reported FY2025 revenue of $24.568B, up 2.9% YoY
2025-09-10Launched fully automated BD-Tau research-use-only immunoassay for neurodegenerative research
2025-03-18Life Sciences launched CytoFLEX mosaic spectral flow cytometry with up to 88 channels
2025-03-10Received FDA 510(k) clearance for DxC 500i clinical chemistry and immunoassay analyzer
2025-01-28Received FDA Breakthrough Device Designation for an Alzheimer's blood test
2011-06-30Danaher Corporation completed acquisition of Beckman Coulter

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE